Published in Leuk Lymphoma on May 01, 2010
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice. J Immunol (2015) 0.86
Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review. J Thorac Dis (2013) 0.83
Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol (2013) 0.80
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. Cancer Res Treat (2014) 0.78
A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma (2010) 0.77
A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection. Int J Organ Transplant Med (2011) 0.76
Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLoS One (2015) 0.75
Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol. Clin Case Rep (2015) 0.75
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood (2012) 2.21
Effective treatment of Waldenström macroglobulinemia associated pure red cell aplasia with standard antilymphomatous chemotherapy. Leuk Lymphoma (2013) 1.92
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood (2004) 1.57
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma (2014) 1.47
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymphoma (2010) 1.41
Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. J Clin Oncol (2013) 1.39
A case of systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma associated with hypereosinophilia, granulomatous myositis and vasculitis. Leuk Lymphoma (2012) 1.39
Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol (2003) 1.22
The symptom burden of patients with hematological malignancy: a cross-sectional observational study. J Pain Symptom Manage (2011) 1.18
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol (2007) 1.10
Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther (2012) 1.01
The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation (2006) 0.98
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. Int J Stroke (2013) 0.93
Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol (2011) 0.92
The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. Genes Chromosomes Cancer (2010) 0.89
Targeted disruption of SPI3/Serpinb6 does not result in developmental or growth defects, leukocyte dysfunction, or susceptibility to stroke. Mol Cell Biol (2004) 0.89
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma (2007) 0.85
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma (2013) 0.85
Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma (2010) 0.85
Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol (2005) 0.85
'Leukaemic' presentation of metastatic Merkel cell carcinoma. Br J Haematol (2005) 0.84
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.82
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Cancer (2007) 0.81
Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase. Immunol Cell Biol (2012) 0.80
Increased coated-platelet levels in chronic haemodialysis patients. Nephrology (Carlton) (2009) 0.80
Venous thromboembolism prevention in patients undergoing colorectal surgery for cancer. ANZ J Surg (2013) 0.79
Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymphoma (2015) 0.78
CGH and SNP array using DNA extracted from fixed cytogenetic preparations and long-term refrigerated bone marrow specimens. Mol Cytogenet (2012) 0.78
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol (2015) 0.77
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma (2009) 0.77
High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone? Leuk Lymphoma (2013) 0.77
Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis. Leuk Res (2007) 0.77
Src family kinases and their role in hematological malignancies. Leuk Lymphoma (2015) 0.77
Association between early peak temperature and mortality in neutropenic sepsis. Ann Hematol (2014) 0.76
Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre. Histopathology (2012) 0.76
Thromboprophylaxis use in medical and surgical inpatients and the impact of an electronic risk assessment tool as part of a multi-factorial intervention. A report on behalf of the elVis study investigators. J Thromb Thrombolysis (2011) 0.76
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol (2013) 0.76
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis (2008) 0.76
The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood (2006) 0.76
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.75
All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. Eur J Haematol (2013) 0.75
ABVD versus BEACOPP for Hodgkin's lymphoma. N Engl J Med (2011) 0.75
The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal? Leuk Lymphoma (2010) 0.75
CD38 expression in CLL: a dynamic marker of prognosis. Leuk Lymphoma (2013) 0.75
Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment. Haematologica (2012) 0.75
Hodgkin's disease associated cholestasis in a man with thymoma. Pathology (2003) 0.75
Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation. Leuk Lymphoma (2012) 0.75
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. Leuk Res (2007) 0.75
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leuk Lymphoma (2014) 0.75
Favourable outcome of pulmonary zygomycosis in haematological malignancy. Pathology (2006) 0.75
New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. Leuk Lymphoma (2010) 0.75